Tobias Nordström, MD, on follow-up data from the STHLM3 trial

Author(s):

Key Takeaways

The STHLM3 trial screened nearly 60,000 men using PSA and STHLM3 tests, combining genetic and protein biomarkers with clinical data.
Men with positive test results underwent systematic biopsy, and follow-up assessed outcomes post-radical prostatectomy.
Findings indicate that men with PSA below 3 but elevated STHLM3 results have a substantial risk of biochemical recurrence.
STHLM3 testing may identify aggressive prostate cancer cases that PSA screening alone could miss.

“We can now see that we can find a proportion of those men that have an elevated STHLM3 tests that actually have a quite substantial risk of biochemical recurrence after the radical prostatectomy,” says Tobias Nordström, MD, PhD.

In this video, Tobias Nordström, MD, PhD, shares key findings from the study,“Are we missing aggressive cancer with PSA screening alone? Biochemical recurrence after radical prostatectomy: Evidence from the STHLM3 trial (NCT03639649),” which he presented at the Society of Urologic Oncology 25th Annual Meeting in Dallas, Texas. Nordström is a clinical urologist and prostate cancer researcher at Karolinska Institutet in Sweden.

Could you share some background on the STHLM3trial?

The STHLM3 study, the original study, is from 2015. It was almost 60,000 men that were invited to screening by invitation in Stockholm, Sweden. They were between 50 and 69 years old. They had 2 blood tests. So, it's the PSA test and the STHLM3 test, which is a combination of genetic biomarkers, protein biomarkers, and clinical information. If any of those tests were positive, with a PSA above 3 or STHLM3 test above 11, they had a traditional systematic biopsy. We have now had the opportunity of assessing the outcomes of the men having a radical prostatectomy as a follow-up of that study.

What were the key findings?

What we see now is that we have some follow-up of the men undergoing a radical prostatectomy. What's special about this cohort that we also include men that had a PSA below 3 and thereby having a STHLM3 test. We know from before that a significant proportion of men also with a PSA below 3 have findings of significant prostate cancer. We can now see that we can find a proportion of those men that have an elevated STHLM3 tests that actually have a quite substantial risk of biochemical recurrence after the radical prostatectomy.

This transcript was AI generated and edited by human editors for clarity.